Literature DB >> 24464213

Checkpoint kinase 1 is negatively regulated by miR-497 in hepatocellular carcinoma.

Yin Xie1, Rong-Rong Wei, Guo-Liang Huang, Mei-Yin Zhang, Yun-Fei Yuan, Hui-Yun Wang.   

Abstract

Checkpoint kinase 1 (CHEK1) is an evolutionarily conserved Ser/Thr kinase, which mediates cell-cycle arrest after DNA damage, and we previously reported that CHEK1 was overexpressed and associated with poor prognosis in hepatocellular carcinoma (HCC), indicating it was oncogenic gene. In this study, we aimed to elucidate the mechanism of CHEK1 overexpression in HCC. We first verified the upregulated CHEK1 by qRT-PCR and western blot in 30 HCC samples compared with corresponding non-tumor liver tissues. In silico analysis showed that CHEK1 was a candidate target of miR-497, which was previously found to be downregulated in HCC by us. To test whether miR-497 could bind to 3'untranslated region (3'UTR) of CHEK1, luciferase reporter assay was conducted. The result revealed that miR-497 could bind to the 3'untranslated region (3'UTR) of CHEK1 mRNA. Western blot showed that ectopic expression of miR-497 suppressed the CHEK1 expression and inhibition of miR-497 led to significant upregulation of CHEK1. Finally, miR-497 expression was measured in the same 30 HCC samples, and the correlation between miR-497 and CHEK1 was analyzed. The results indicated that miR-497 was downregulated in HCC and had a significant negative correlation with CHEK1. Taken together, these results demonstrated that CHEK1 was negatively regulated by miR-497, and the overexpressed CHEK1 was resulted from the downregulated miR-497 in HCC, which provided a potential molecular target for HCC therapy.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24464213     DOI: 10.1007/s12032-014-0844-4

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  27 in total

1.  Stat3-mediated activation of microRNA-23a suppresses gluconeogenesis in hepatocellular carcinoma by down-regulating glucose-6-phosphatase and peroxisome proliferator-activated receptor gamma, coactivator 1 alpha.

Authors:  Bo Wang; Shu-Hao Hsu; Wendy Frankel; Kalpana Ghoshal; Samson T Jacob
Journal:  Hepatology       Date:  2012-06-05       Impact factor: 17.425

2.  miR-200a-mediated downregulation of ZEB2 and CTNNB1 differentially inhibits nasopharyngeal carcinoma cell growth, migration and invasion.

Authors:  Hongping Xia; Samuel S Ng; Songshan Jiang; William K C Cheung; Johnny Sze; Xiu-Wu Bian; Hsiang-Fu Kung; Marie C Lin
Journal:  Biochem Biophys Res Commun       Date:  2009-11-24       Impact factor: 3.575

3.  Chaperoning checkpoint kinase 1 (Chk1), an Hsp90 client, with purified chaperones.

Authors:  Sonnet J H Arlander; Sara J Felts; Jill M Wagner; Bridget Stensgard; David O Toft; Larry M Karnitz
Journal:  J Biol Chem       Date:  2005-12-05       Impact factor: 5.157

4.  Differential expression of microRNA species in human gastric cancer versus non-tumorous tissues.

Authors:  Junming Guo; Ying Miao; Bingxiu Xiao; Rong Huan; Zhen Jiang; Dan Meng; Yanjun Wang
Journal:  J Gastroenterol Hepatol       Date:  2008-11-03       Impact factor: 4.029

5.  Changes in microRNA expression levels correlate with clinicopathological features and prognoses in endometrial serous adenocarcinomas.

Authors:  Eri Hiroki; Jun-Ichi Akahira; Fumihiko Suzuki; Satoru Nagase; Kiyoshi Ito; Takashi Suzuki; Hironobu Sasano; Nobuo Yaegashi
Journal:  Cancer Sci       Date:  2009-10-08       Impact factor: 6.716

6.  Clinical significance and prognostic value of microRNA expression signatures in hepatocellular carcinoma.

Authors:  Rongrong Wei; Guo-Liang Huang; Mei-Yin Zhang; Bin-Kui Li; Hui-Zhong Zhang; Ming Shi; Xiao-Qian Chen; Long Huang; Qing-Ming Zhou; Wei-Hua Jia; X F Steven Zheng; Yun-Fei Yuan; Hui-Yun Wang
Journal:  Clin Cancer Res       Date:  2013-06-28       Impact factor: 12.531

Review 7.  New insights into checkpoint kinase 1 in the DNA damage response signaling network.

Authors:  Yun Dai; Steven Grant
Journal:  Clin Cancer Res       Date:  2010-01-12       Impact factor: 12.531

8.  Identification of novel kinase targets for the treatment of estrogen receptor-negative breast cancer.

Authors:  Corey Speers; Anna Tsimelzon; Krystal Sexton; Ashley M Herrick; Carolina Gutierrez; Aedin Culhane; John Quackenbush; Susan Hilsenbeck; Jenny Chang; Powel Brown
Journal:  Clin Cancer Res       Date:  2009-10-06       Impact factor: 12.531

9.  The E2F-regulated gene Chk1 is highly expressed in triple-negative estrogen receptor /progesterone receptor /HER-2 breast carcinomas.

Authors:  Lieve Verlinden; Isabelle Vanden Bempt; Guy Eelen; Maria Drijkoningen; Ilse Verlinden; Kathleen Marchal; Christiane De Wolf-Peeters; Marie-Rose Christiaens; Luc Michiels; Roger Bouillon; Annemieke Verstuyf
Journal:  Cancer Res       Date:  2007-07-15       Impact factor: 12.701

10.  MicroRNA-497 targets insulin-like growth factor 1 receptor and has a tumour suppressive role in human colorectal cancer.

Authors:  S T Guo; C C Jiang; G P Wang; Y P Li; C Y Wang; X Y Guo; R H Yang; Y Feng; F H Wang; H-Y Tseng; R F Thorne; L Jin; X D Zhang
Journal:  Oncogene       Date:  2012-06-18       Impact factor: 9.867

View more
  39 in total

1.  A selective screening platform reveals unique global expression patterns of microRNAs in a cohort of human soft-tissue sarcomas.

Authors:  Peter Y Yu; Mumtaz Y Balkhi; Katherine J Ladner; Hansjuerg Alder; Lianbo Yu; Xiaokui Mo; William G Kraybill; Denis C Guttridge; O Hans Iwenofu
Journal:  Lab Invest       Date:  2016-02-15       Impact factor: 5.662

2.  Downregulation of microRNA-497 is associated with upregulation of synuclein γ in patients with osteosarcoma.

Authors:  Liang Wang; Hongwei Gao; Ningji Gong; Mingzhi Gong
Journal:  Exp Ther Med       Date:  2016-10-26       Impact factor: 2.447

Review 3.  MicroRNAs in adrenal tumors: relevance for pathogenesis, diagnosis, and therapy.

Authors:  Peter Igaz; Ivan Igaz; Zoltán Nagy; Gábor Nyírő; Peter M Szabó; András Falus; Attila Patócs; Károly Rácz
Journal:  Cell Mol Life Sci       Date:  2014-10-09       Impact factor: 9.261

4.  microRNA-497 overexpression decreases proliferation, migration and invasion of human retinoblastoma cells via targeting vascular endothelial growth factor A.

Authors:  Jianjun Li; Yinghui Zhang; Xiuchao Wang; Ruibo Zhao
Journal:  Oncol Lett       Date:  2017-04-24       Impact factor: 2.967

Review 5.  Cell cycle proteins as promising targets in cancer therapy.

Authors:  Tobias Otto; Piotr Sicinski
Journal:  Nat Rev Cancer       Date:  2017-01-27       Impact factor: 60.716

Review 6.  Mini but mighty: microRNAs in the pathobiology of periodontal disease.

Authors:  Moritz Kebschull; Panos N Papapanou
Journal:  Periodontol 2000       Date:  2015-10       Impact factor: 7.589

7.  MicroRNA-497 suppresses osteosarcoma tumor growth in vitro and in vivo.

Authors:  Liang Ge; Baisong Zheng; Minghe Li; Liang Niu; Zhihong Li
Journal:  Oncol Lett       Date:  2016-01-29       Impact factor: 2.967

8.  TAp63-Regulated miRNAs Suppress Cutaneous Squamous Cell Carcinoma through Inhibition of a Network of Cell-Cycle Genes.

Authors:  Andrew John Davis; Maksym Tsinkevich; Jason Rodencal; Hussein A Abbas; Xiao-Hua Su; Young-Jin Gi; Bin Fang; Kimal Rajapakshe; Cristian Coarfa; Preethi H Gunaratne; John M Koomen; Kenneth Y Tsai; Elsa R Flores
Journal:  Cancer Res       Date:  2020-03-10       Impact factor: 12.701

9.  miR-497 inhibits epithelial mesenchymal transition in breast carcinoma by targeting Slug.

Authors:  Zhihao Wu; Xiangli Li; Xuehong Cai; Chenggang Huang; Min Zheng
Journal:  Tumour Biol       Date:  2015-12-23

Review 10.  Current Implications of microRNAs in Genome Stability and Stress Responses of Ovarian Cancer.

Authors:  Arkadiusz Gajek; Patrycja Gralewska; Agnieszka Marczak; Aneta Rogalska
Journal:  Cancers (Basel)       Date:  2021-05-29       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.